Table 1:

Major demographic and clinical parameters of 30 patients with psoriasis

Patient	Gender	Age	Age of disease’s Onset	Previous Treatment*	Washout Period (months)	Current Treatment	Response to treatment
							Baseline PASI	3 months PASI
1	M	51	48	cDMARDS, apremilast	6	Secukinumab	21.6	0
2	M	66	46	Naïve	n/a	Secukinumab	21	0.5
3	M	53	29	Cyclosporine, retinoids	n/a	Secukinumab	20	0
4	M	53	41	Naïve	n/a	Secukinumab	11.9	0
5	M	65	55	Cyclosporine, retinoids	n/a	Brodalumab	18.5	1.4
6	F	38	31	Naïve	n/a	Brodalumab	10	0
7	M	52	48	Etanercept	34	Brodalumab	12.8	1.7
8	M	70	60	Ustekinumab, secukinumab, apremilast	1	Brodalumab	10	20
9	F	37	26	cDMARDS	n/a	Brodalumab	8.1	0.5
10	M	49	43	Retinoids, cDMARDS	n/a	Secukinumab	11.6	1.5
11	M	64	25	Naïve	n/a	Brodalumab	25.5	2.3
12	M	67	60	Apremilast	0	Brodalumab	30	2.8
13	M	67	53	Adalimumab, cDMARDS, etanercept, cyclosporine, apremilast	1	Secukinumab	10.4	0
14	M	44	37	cDMARDS, cyclosporine, etanercept, ustekinumab	1	Secukinumab	14.1	1.2
15	M	45	42	cDMARDS, adalimumab	3	Secukinumab	13.2	0
16	F	63	19	cDMARDS, cyclosporine, etanercept, ustekinumab	0	Secukinumab	11.9	0.5
17	F	57	51	cDMARDS, cyclosporine, retinoids, ustekinumab	0	Secukinumab	21.2	1.8
18	F	27	18	Naïve	n/a	Secukinumab	17	1.2
19	M	61	32	cDMARDS, cyclosporine	n/a	Secukinumab	8.5	0
20	M	41	27	ustekinumab, adalimumab	13	Brodalumab	7.8	0
21	M	50	34	cDMARDS	n/a	Secukinumab	10.9	0.4
22	F	49	36	cDMARDS, etanercept, ustekinumab	0	Brodalumab	8.5	2.8
23	F	52	43	Retinoids, cDMARDs, ustekinumab, secukinumab	1	Brodalumab	13.5	4.6
24	F	39	26	cDMARDS	n/a	Brodalumab	18	4.1
25	F	62	29	cDMARDS	n/a	Secukinumab	8	1.8
26	F	54	48	Naïve	n/a	Secukinumab	26.6	2.2
27	F	48	38	cDMARDS, etanercept	1	Secukinumab	13.5	1.2
28	F	57	35	ustekinumab	5	Brodalumab	7.2	0
29	F	66	46	cDMARDS, adalimumab	0	Secukinumab	20.5	16.2
30	M	46	60	cDMARDS, etanercept, ustekinumab	1	Secukinumab	11	10.5

Treatment in chronological order.

Abbreviation: PASI, Psoriasis Area and Severity Index; F, female; M, male; naive patient naïve to biologic treatment; cDMARDs conventional disease-modifying anti-rheumatic drugs; washout period months since last biologic or apremilast therapy; n/a patient has not received prior biologic or apremilast treatment.s